# Charles River Laboratories International (CRL) — Earnings

CRL · NYSE · Stock

Canonical page: https://www.lighthorse.io/tickers/crl/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2026 |
| Period end | Jun 27, 2026 |
| EPS actual | $3.02 |
| EPS estimate | $2.74 |
| EPS surprise | +10.13% |
| Revenue surprise | +2.75% |
| Revenue | $1.0B |
| Revenue estimate | $977.2M |
| Reported | Aug 5, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1100682/000110068226000118/crl-20260627.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/d5ac4f89-e5dd-1a0e-964d-cb16fb1c8b55.html) |

Charles River Laboratories reported Q2 2026 results on August 5, 2026. Earnings per share came in at $3.02, ahead of the $2.74 estimate by 10.13%. Revenue was about $1.0 billion, 2.75% above the $977.2 million consensus. Compared with Q2 2025, EPS fell about 3% from $3.12, while revenue was roughly flat. EPS rose about 47% from Q1's $2.06, the low in the table.

The longer record shows a gradual decline in earnings on steady sales. Annual EPS slipped each year, from $11.13 in 2022 to $10.65 in 2023, $10.32 in 2024 and $10.28 in 2025, a drop of about 8%. Quarterly revenue has held close to $1.0 billion since 2022. The first half of 2026 adds up to $5.08 per share, about 7% below the first half of 2025. Q2 2025 holds the EPS high in the table at $3.12. Charles River beat the EPS estimate in all 20 quarters shown. The largest beat was 24.69% in Q2 2025, and the smallest was 1.16% in Q2 2022.

Charles River reported Q3 results between November 2 and November 8 in each of the past five years. That points to early November 2026 for the next report.

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2026 | Aug 5, 2026 | $2.74 | $3.02 | 10.13% | $977.2M | $1.0B |
| Q1 2026 | May 7, 2026 | $1.94 | $2.06 | 6.00% | $977.5M | $995.8M |
| Q4 2025 | Feb 18, 2026 | $2.34 | $2.39 | 1.98% | $986.7M | $994.2M |
| Q3 2025 | Nov 5, 2025 | $2.34 | $2.43 | 3.95% | $990.8M | $1.0B |
| Q2 2025 | Aug 6, 2025 | $2.50 | $3.12 | 24.69% | $985.2M | $1.0B |
| Q1 2025 | May 7, 2025 | $2.08 | $2.34 | 12.73% | $942.0M | $984.2M |
| Q4 2024 | Feb 19, 2025 | $2.53 | $2.66 | 5.24% | $983.6M | $1.0B |
| Q3 2024 | Nov 6, 2024 | $2.42 | $2.59 | 6.91% | $976.0M | $1.0B |
| Q2 2024 | Aug 7, 2024 | $2.39 | $2.80 | 16.95% | $1.0B | $1.0B |
| Q1 2024 | May 9, 2024 | $2.06 | $2.27 | 9.93% | $992.3M | $1.0B |
| Q4 2023 | Feb 14, 2024 | $2.40 | $2.46 | 2.42% | $991.3M | $1.0B |
| Q3 2023 | Nov 8, 2023 | $2.36 | $2.72 | 15.40% | $1.0B | $1.0B |
| Q2 2023 | Aug 9, 2023 | $2.64 | $2.69 | 1.96% | $1.1B | $1.1B |
| Q1 2023 | May 11, 2023 | $2.59 | $2.78 | 7.40% | $986.3M | $1.0B |
| Q4 2022 | Feb 22, 2023 | $2.75 | $2.98 | 8.55% | $1.0B | $1.1B |
| Q3 2022 | Nov 2, 2022 | $2.50 | $2.63 | 5.09% | $970.4M | $989.2M |
| Q2 2022 | Aug 3, 2022 | $2.74 | $2.77 | 1.16% | $995.2M | $973.1M |
| Q1 2022 | May 4, 2022 | $2.72 | $2.75 | 1.18% | $910.1M | $913.9M |
| Q4 2021 | Feb 16, 2022 | $2.43 | $2.49 | 2.38% | $888.3M | $905.0M |
| Q3 2021 | Nov 3, 2021 | $2.58 | $2.70 | 4.48% | $906.9M | $895.9M |

## Frequently Asked Questions

### When did Charles River Laboratories International (CRL) last report earnings?

Charles River Laboratories International last reported on Aug 5, 2026, covering fiscal Q2 2026.

### Did CRL beat earnings estimates?

Yes. Charles River Laboratories International reported EPS of $3.02 for Q2 2026 against a $2.74 estimate — a 10.13% beat.

### How much revenue did CRL report last quarter?

Charles River Laboratories International reported $1.0B in revenue for Q2 2026, against a consensus estimate of $977.2M.

## Similar Stocks

- [IQV](https://www.lighthorse.io/tickers/iqv) — IQVIA Holdings, Inc. Common Stock
- [RVTY](https://www.lighthorse.io/tickers/rvty) — Revvity, Inc. Common Stock
- [TECH](https://www.lighthorse.io/tickers/tech) — Bio-Techne Corp - Common Stock
- [TMO](https://www.lighthorse.io/tickers/tmo) — Thermo Fisher Scientific Inc Common Stock
- [A](https://www.lighthorse.io/tickers/a) — Agilent Technologies, Inc. Common Stock
- [ICLR](https://www.lighthorse.io/tickers/iclr) — ICON plc - Ordinary Shares

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).